228 related articles for article (PubMed ID: 32369845)
1. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
3. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
[TBL] [Abstract][Full Text] [Related]
4. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
6. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
8. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
Walsh KS; Mrakotsky C; Carcao M; Chan AKC; Nielsen PH; Holst H; Shapiro K
Res Pract Thromb Haemost; 2024 Feb; 8(2):102341. PubMed ID: 38516633
[TBL] [Abstract][Full Text] [Related]
9. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding.
Sun J; Livingston EW; Broberg ML; Johansen PB; Ley CD; Knudsen T; Ezban M; Bateman T; Monahan PE; Taves S
J Thromb Haemost; 2019 Aug; 17(8):1240-1246. PubMed ID: 31148392
[TBL] [Abstract][Full Text] [Related]
11. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
[TBL] [Abstract][Full Text] [Related]
12. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
[TBL] [Abstract][Full Text] [Related]
14. Nonacog Beta Pegol: A Review in Haemophilia B.
Syed YY
Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
[TBL] [Abstract][Full Text] [Related]
15. GlycoPEGylated recombinant factor IX for hemophilia B in context.
Santagostino E; Mancuso ME
Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
[TBL] [Abstract][Full Text] [Related]
16. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM; Rendo P; Smith L; Altisent C
Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
[TBL] [Abstract][Full Text] [Related]
18. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
Yang R; Wu R; Sun J; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC; Rendo P
Medicine (Baltimore); 2021 May; 100(21):e26077. PubMed ID: 34032739
[TBL] [Abstract][Full Text] [Related]
19. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
